Evolv Technologies Holdings, Inc.·4

Jun 22, 4:02 PM ET

Ellenbogen Michael 4

4 · Evolv Technologies Holdings, Inc. · Filed Jun 22, 2026

Research Summary

AI-generated summary of this filing

Updated

Evolv (EVLV) Director Michael Ellenbogen Receives RSU Award

What Happened Michael Ellenbogen, a director of Evolv Technologies Holdings, Inc. (EVLV), was granted 28,318 restricted stock units (RSUs) on June 18, 2026. The award is recorded at $0.00 per RSU (no cash paid or received) and is a derivative grant that represents the right to receive one share of Class A common stock per RSU upon vesting. This is an equity award (grant), not an open-market purchase or sale.

Key Details

  • Transaction date: 2026-06-18; Filing date: 2026-06-22 (filed within the standard two-business-day Form 4 window).
  • Award: 28,318 RSUs; reported price: $0.00; immediate cash value: $0.
  • Shares owned after transaction: Not specified in the provided filing.
  • Footnote highlights:
    • F1: Each RSU converts to one share of Class A common stock; RSUs have no expiration.
    • F2: RSUs vest in full at the earlier of June 18, 2027 or the day before the issuer's next annual meeting.
  • Transaction type: A (Award/Grant) — derivative grant, not a purchase (code A).

Context RSU grants are common compensation for executives and directors and do not involve immediate cash flow; their ultimate value depends on Evolv's share price when the RSUs vest and are settled. Because this was a grant (not a sale), it typically reflects compensation or retention incentives rather than a direct signal of buying or selling intent.

Insider Transaction Report

Form 4
Period: 2026-06-18
Transactions
  • Award

    Restricted Stock Units

    [F1][F2]
    2026-06-18+28,31828,318 total
    Class A Common Stock (28,318 underlying)
Footnotes (2)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock. The RSUs have no expiration date.
  • [F2]The RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the Issuer's next annual meeting date.
Signature
/s/ Rachel Roy, Attorney-in-fact for Michael Ellenbogen|2026-06-22

Documents

1 file
  • 4
    wk-form4_1782158565.xmlPrimary

    FORM 4